European Union - English - EMA (European Medicines Agency)

acorda therapeutics ireland limited - levodopa - parkinson disease - anti-parkinson drugs - inbrija is indicated for the intermittent treatment of episodic motor fluctuations (off episodes) in adult patients with parkinson’s disease (pd) treated with a levodopa/dopa-decarboxylase inhibitor.

European Union - English - EMA (European Medicines Agency)

boehringer ingelheim international gmbh - pramipexole dihydrochloride monohydrate - restless legs syndrome; parkinson disease - anti-parkinson drugs - mirapexin is indicated for treatment of the signs and symptoms of idiopathic parkinson's disease, alone (without levodopa) or in combination with levodopa, i.e. over the course of the disease, through to late stages when the effect of levodopa wears off or becomes inconsistent and fluctuations of the therapeutic effect occur (end-of-dose or 'on-off' fluctuations).mirapexin is indicated for symptomatic treatment of moderate to severe idiopathic restless-legs syndrome in dosages up to 0.54 mg of base (0.75 mg of salt).

European Union - English - EMA (European Medicines Agency)

boehringer ingelheim international gmbh - pramipexole dihydrochloride monohydrate - restless legs syndrome; parkinson disease - anti-parkinson drugs - sifrol is indicated for treatment of the signs and symptoms of idiopathic parkinson's disease, alone (without levodopa) or in combination with levodopa, i.e. over the course of the disease, though to late stages when the effect of levodopa wears off or becomes inconsistent and fluctuations of the therapeutic effect occur (end-of-dose or 'on-off' fluctuations).sifrol is indicated for symptomatic treatment of moderate to severe idiopathic restless-legs syndrome in dosages up to 0.54 mg of base (0.75 mg of salt).

Israel - English - Ministry of Health

organon pharma israel ltd., israel - carbidopa as monohydrate; levodopa - tablets controlled release - levodopa 200 mg; carbidopa as monohydrate 50 mg - levodopa and decarboxylase inhibitor - levodopa and decarboxylase inhibitor - idiopathic parkinson's disease. postencephalitic parkinsonism. symptomatic parkinsonism. to reduce "off" time in patients previously treated with levodopa/decarboxylase inhibitor preparations, or with levodopa alone, who have had motor fluctuations characterized by end-of-dose deterioration ("wearing-off" phenomenon), peak dose dyskinesias, akinesia, or similar evidence of short-duration motor disturbances.

European Union - English - EMA (European Medicines Agency)

ge healthcare b.v. - ioflupane (123l) - tomography, emission-computed, single-photon; lewy body disease; parkinson disease; alzheimer disease - diagnostic radiopharmaceuticals - this medicinal product is for diagnostic use only.datscan is indicated for detecting loss of functional dopaminergic neuron terminals in the striatum:in adult patients with clinically uncertain parkinsonian syndromes, for example those with early symptoms, in order to help differentiate essential tremor from parkinsonian syndromes related to idiopathic parkinson’s disease, multiple system atrophy and progressive supranuclear palsy. datscan is unable to discriminate between parkinson's disease, multiple system atrophy and progressive supranuclear palsy.in adult patients, to help differentiate probable dementia with lewy bodies from alzheimer’s disease. datscan is unable to discriminate between dementia with lewy bodies and parkinson’s disease dementia.

European Union - English - EMA (European Medicines Agency)

ucb pharma s.a. - rotigotine - restless legs syndrome; parkinson disease - anti-parkinson drugs - parkinson's disease: neupro is indicated for the treatment of the signs and symptoms of early-stage idiopathic parkinson's disease as monotherapy (i.e. without levodopa) or in combination with levodopa, i.e. over the course of the disease, through to late stages when the effect of levodopa wears off or becomes inconsistent and fluctuations of the therapeutic effect occur (end of dose or 'on-off' fluctuations).restless-legs syndrome: neupro is indicated for the symptomatic treatment of moderate to severe idiopathic restless-legs syndrome in adults.

European Union - English - EMA (European Medicines Agency)

mylan s.a.s. - rasagiline tartrate - parkinson disease - anti-parkinson drugs - rasagiline mylan is indicated for the treatment of idiopathic parkinson’s disease (pd) as monotherapy (without levodopa) or as adjunct therapy (with levodopa) in patients with end of dose fluctuations.

European Union - English - EMA (European Medicines Agency)

orion corporation - levodopa, carbidopa, entacapone - parkinson disease - nervous system - levodopa/carbidopa/entacapone orion is indicated for the treatment of adult patients with parkinson's disease and end-of-dose motor fluctuations not stabilised on levodopa / dopa-decarboxylase (ddc)-inhibitor treatment.

European Union - English - EMA (European Medicines Agency)

ucb pharma s.a.   - rotigotine - restless legs syndrome; parkinson disease - anti-parkinson drugs - leganto is indicated for the symptomatic treatment of moderate to severe idiopathic restless-legs syndrome in adults.leganto is indicated for the treatment of the signs and symptoms of early-stage idiopathic parkinson’s disease as monotherapy (i.e. without levodopa) or in combination with levodopa, i.e. over the course of the disease, through to late stages when the effect of levodopa wears off or becomes inconsistent and fluctuations of the therapeutic effect occur (end of dose or ‘on-off’ fluctuations).

New Zealand - English - Medsafe (Medicines Safety Authority)

organon (new zealand) limited - carbidopa monohydrate 54mg equivalent to carbidopa 50 mg; levodopa 200mg; carbidopa monohydrate 54mg equivalent to carbidopa 50 mg; levodopa 200mg; carbidopa monohydrate 54mg equivalent to carbidopa 50 mg; levodopa 200mg - modified release tablet - 50/200 - active: carbidopa monohydrate 54mg equivalent to carbidopa 50 mg levodopa 200mg excipient: allura red ac hyprolose hypromellose indigo carmine magnesium stearate active: carbidopa monohydrate 54mg equivalent to carbidopa 50 mg levodopa 200mg excipient: hyprolose crotonic acid-polyvinylacetate copolymer iron oxide red magnesium stearate quinoline yellow aluminium lake active: carbidopa monohydrate 54mg equivalent to carbidopa 50 mg levodopa 200mg excipient: hyprolose crotonic acid-polyvinylacetate copolymer iron oxide red magnesium stearate quinoline yellow aluminium lake - idiopathic parkinson's disease postencephalitic parkinsonism symptomatic parkinsonism (carbon monoxide or manganese intoxication) patients with parkinson's disease or parkinsonism who are taking vitamin preparations that contain pyridoxine to reduce "off" time in patients previously treated with levodopa/decarboxylase inhibitor preparations, or with levodopa alone, who have had motor fluctuations characterised by end-of-dose deterioration ("wearing-off" phenomenon), peak dose dyskinesias, akinesia, or similar evidence of short-duration motor disturbances.